GPT-Rosalind

OpenAI introduces a new model update to GPT-Rosalind, designed for life sciences research at enterprise scale. The updated model combines GPT-5.5's agentic coding and tool-use capabilities with stronger model intelligence in core drug-discovery domains such as medicinal chemistry and genomics. GPT-Rosalind shows broad performance gains on research tasks from biology experts, complex medicinal chemistry queries, quantitative biology, and wet lab troubleshooting.

OpenAI is taking steps to accelerate defensive progress in biology, including launching Rosalind Biodefense and expanding trusted access to GPT-Rosalind for select U.S. government and allied partners.

GPT-Rosalind's major upgrade integrates GPT-5.5's agentic coding and tool-use capabilities, significantly boosting enterprise-grade AI efficacy in drug discovery, analysis, and experimental workflows.